A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged ¡Ý 66 years .
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Selinexor (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms HOVON 103 AML
- 12 Apr 2017 Status changed from not yet recruiting to recruiting.
- 14 Jul 2016 New trial record